Development of Novel Second Generation DC/Tumor Fusion Vaccine in Lymphoma
Shira Orr(Beth Israel Deaconess Medical Center), David Avigan(Beth Israel Deaconess Medical Center), Haider Ghiasuddin(Beth Israel Deaconess Medical Center), Jon Arnason(Beth Israel Deaconess Medical Center), Robin Joyce(Beth Israel Deaconess Medical Center), Jacalyn Rosenblatt(Beth Israel Deaconess Medical Center), Donald Küfe(Dana-Farber Cancer Institute), Myrna Nahas, Salvia Jain(Broad Institute), Adam Morin(Beth Israel Deaconess Medical Center), Lina Bisharat(Beth Israel Deaconess Medical Center), Dina Stroopinsky(Beth Israel Deaconess Medical Center), Shufen Meng(Beth Israel Deaconess Medical Center), Maryam Rahimian(Beth Israel Deaconess Medical Center), Matthew Weinstock(Beth Israel Deaconess Medical Center), Jessica Liegel(Beth Israel Deaconess Medical Center), Marzia Capelletti(Caris Life Sciences (United States))
Cited by 3
Related Papers
Anti-BCMA CAR T-Cell Therapy bb2121 in Relapsed or Refractory Multiple Myeloma
|New England Journal of Medicine|2019|1.7k
Randomized Controlled Trial of Yttrium-90–Labeled Ibritumomab Tiuxetan Radioimmunotherapy Versus Rituximab Immunotherapy for Patients With Relapsed or Refractory Low-Grade, Follicular, or Transformed B-Cell Non-Hodgkin’s Lymphoma
|Journal of Clinical Oncology|2002|1.2k
Interleukin-2 and Regulatory T Cells in Graft-versus-Host Disease
|New England Journal of Medicine|2011|1.1k
Preexistence and Clonal Selection of MET Amplification in EGFR Mutant NSCLC
|Cancer Cell|2010|1.1k